Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 10/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | PAX8 | Q06710 | 4/20 | 0.48 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3895665 | 0.92 | GPBAR1 (0.51) | GPBAR1KMT2AMEN1PAX8LMNA | |
| SCHEMBL3883418 | 0.81 | GPBAR1 (0.58) | GPBAR1KMT2APOLBLMNARECQL | |
| SCHEMBL3884750 | 0.79 | ROCK1 (0.60) | GPBAR1PAX8 | |
| SCHEMBL4318459 | 0.79 | GPBAR1 (0.56) | GPBAR1KMT2APOLBLMNARECQL | |
| SCHEMBL3892732 | 0.77 | GPBAR1 (0.54) | GPBAR1KMT2APOLBLMNARECQL | |
| SCHEMBL3885330 | 0.76 | GPBAR1 (0.72) | GPBAR1KMT2AMEN1POLBLMNA | |
| SCHEMBL30646811 | 0.72 | CCR2 (0.46) | KMT2AMEN1 | |
| SCHEMBL29617629 | 0.72 | CCR2 (0.46) | KMT2AMEN1 | |
| SCHEMBL17478079 | 0.71 | GPBAR1 (1.00) | GPBAR1 | |
| SCHEMBL3888040 | 0.69 | GPBAR1 (0.51) | GPBAR1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592357-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| EP-1718638-A4 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20080058384-A1 | Novel Compounds | GLAXOSMITHKLINE LLC | 2008-03-06 | — | — | US | disclosed |
| EP-1718638-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005082890-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058384-A1 | Novel Compounds | ARHGDIB, TNK2, ROCK2 | GPBAR1 2826/4885KMT2A 3760/4885MEN1 4332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.